Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 19 Show results per page	View Search Criteria \| Help With Results

Last Modified: 9/26/2006 First Published: 12/1/1996


1.		Phase III Randomized Study of Vincristine, Doxorubicin, and Dexamethasone (VAD) With Or Without PSC 833 in Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				E-1A95 CAN-NCIC-MY8, CLB-E1A95, EORTC-E1A95/06971, SWOG-E1A95, CAN-NCIC-J1A95, CLB-9596, SWOG-S1A95, NCT00002878, E1A95, MY8

Last Modified: 7/11/2007


2.		Phase III Randomized Study of Mitoxantrone/Etoposide/Cytarabine (MEC) versus MEC Plus PSC 833 (PSC MEC) in Patients with Recurrent or Refractory Acute Myelogenous Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				15 to 70				NCI				E-2995 E2995

Last Modified: 12/10/2007 First Published: 6/1/2000


3.		Phase III Randomized Study of Intensive Versus Nonintensive Chemotherapy in Older Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				60 and over				Other				LRF-AML14 EU-20016, NCT00005823, ISRCTN62207270

Last Modified: 12/1/1995


4.		Phase I/II Study of DHAD/VP-16 with PSC 833 as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (Summary Last Modified 12/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				17 and over								MDA-DM-94052 NCI-V95-0604

Last Modified: 10/30/2008 First Published: 3/1/1997


5.		Phase I Study of PSC 833 with a Pilot Study of Cytogenetic Risk Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy with Interleukin-2 in Previously Untreated Patients with Acute Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				15 to 59				NCI				CLB-9621 NCT00002925, CALGB-9621

Last Modified: 2/1/2001


6.		Phase I/II Study of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-97-C-0074C NCI-T96-0011, T96-0011

Last Modified: 11/1/2005


7.		Phase II Study of Paclitaxel and Oral PSC 833 (a Nonimmunosuppressive Cyclosporine Analogue) in Persistent or Recurrent Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				GOG-126E

Last Modified: 12/28/2006 First Published: 10/1/1996


8.		Phase II Pilot Study of PSC 833 Modulation of Paclitaxel in Women With Recurrent or Metastatic Breast Cancer (Summary Last Modified 04/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				E-1195 NCT00002826, E1195

Last Modified: 6/1/1999


9.		Phase II Study of PSC 833 plus Doxorubicin in Metastatic Breast Cancer Refractory to Anthracyclines or Anthracenediones (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18				NCI				MAYO-943001 NCI-V96-1077

Last Modified: 5/14/2007


10.		Phase II Randomized Study of Paclitaxel Versus Paclitaxel and PSC 833 in Advanced Breast Cancer (Recurring Less Than 2 Years Since Adjuvant or as Second Line for Advanced Disease) (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				NCI				CHNMC-96002 NCI-H97-1137, NCT00002937

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute